Druck Icon

Eckert & Ziegler Officially Requests Special IBt Shareholder Meeting

Berlin, January 8, 2010 - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) has officially instructed the statutory auditor of publicly listed Belgian seed manufacturer International Brachytherapy S.A. (IBt) to convene, as quickly as feasible, a special general meeting of the shareholders of IBt. Sole item on the agenda is the replacement of IBt non-executive board member H&H Capital Management BVBA, represented by its sole director and Creafund representative Herman Wielfaert, by a representative of Steglitz Medinvest UG (SMI), who together with Eckert & Ziegler on 28 December 2009 initiated a public take-over bid for IBt. SMI, which holds about 22% of the shares in IBt, has so far not been represented on IBt's board at all.

"SMI is a party to the take-over bid and a large IBt shareholder, so it is natural that it should also nominate at least one member of the IBt board", explains Andreas Eckert, CEO of Eckert & Ziegler. "Creafund, on the other hand, has spent considerable effort and money in suing Eckert & Ziegler and SMI for a cash offer for IBt shares. Now that we have voluntarily, and at a substantial effort, complied with Creafund's wishes, we would in any way expect that Creafund accepts the offer and vacates his board seat."

Eckert & Ziegler currently owns about 29% of the shares of IBt and is represented on the board by two non executive directors. Four other directors of the board are independent. Three are Executive Directors that compose the management team. Together with the SMI representative the new board would have ten directors, the maximum amount of incumbents allowed by IBt's articles of association.

The Board of Directors